We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage
News

Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage

Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage
News

Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ad hoc Announcement in Accordance with §15 WpHG Continuation of the SAPHIRE Study into the Second Recruitment Stage"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, has announced the decision to advance the Phase II Hodgkin’s lymphoma (HL) SAPHIRE study with the HDAC inhibitor resminostat into the second Simon stage of patient recruitment.

This decision is based on the analysis of radiological imaging data from patients treated in the first Simon stage through an independent central assessment committee, which confirmed the achievement of the clinical activity requirements for the advancement of the trial.

4SC announced that the first patient had been treated in this trial on January 12, 2010. The Phase II SAPHIRE trial will continue into its second stage of patient recruitment and final results are expected, as planned, in the second half of 2011.
Advertisement